نتایج جستجو برای: exemestane

تعداد نتایج: 576  

Journal: :International Journal of Pharmacy and Pharmaceutical Sciences 2017

2014
Olivia Pagani Meredith M. Regan Barbara A. Walley Tom Baker Gini F. Fleming Marco Colleoni István Láng Henry L. Gomez Carlo Tondini Harold J. Burstein Edith A. Perez Eva Ciruelos Vered Stearns Hervé R. Bonnefoi Silvana Martino Charles E. Geyer Graziella Pinotti Fabio Puglisi Diana Crivellari Thomas Ruhstaller Eric P. Winer Manuela Rabaglio-Poretti Rudolf Maibach Barbara Ruepp Anita Giobbie-Hurder Karen N. Price Jürg Bernhard Weixiu Luo Karin Ribi Giuseppe Viale Alan S. Coates Richard D. Gelber Aron Goldhirsch Prudence A. Francis

Olivia Pagani, M.D., Meredith M. Regan, Sc.D., Barbara A. Walley, M.D., Gini F. Fleming, M.D., Marco Colleoni, M.D., István Láng, M.D., Henry L. Gomez, M.D., Carlo Tondini, M.D., Harold J. Burstein, M.D., Edith A. Perez, M.D., Eva Ciruelos, M.D., Vered Stearns, M.D., Hervé R. Bonnefoi, M.D., Silvana Martino, D.O., Charles E. Geyer, Jr., M.D., Graziella Pinotti, M.D., Fabio Puglisi, M.D., Diana ...

2017
Ugne Sabale Mattias Ekman Daniel Thunström Claire Telford Christopher Livings

OBJECTIVES In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a second-line hormonal therapy for postmenopausal women with estrogen receptor-positive metastatic o...

2018
Takayuki Ueno Shigehira Saji Norikazu Masuda Katsumasa Kuroi Nobuaki Sato Hiroyuki Takei Yutaka Yamamoto Shinji Ohno Hiroko Yamashita Kazufumi Hisamatsu Kenjiro Aogi Hiroji Iwata Takeharu Yamanaka Hironobu Sasano Masakazu Toi

Background Neoadjuvant endocrine therapy (NET) has been demonstrated to improve breast-conserving rate and is a widely accepted treatment option for postmenopausal patients with hormone receptor-positive breast cancer. There are few reports on the association of NET response and long-term outcomes. Objectives To investigate the prognostic value of clinical response to NET. Methods Long-term...

Journal: :Molecular cancer therapeutics 2007
Eric A Ariazi Andrei Leitão Tudor I Oprea Bin Chen Teresa Louis Anne Marie Bertucci Catherine G N Sharma Shaun D Gill Helen R Kim Heather A Shupp Jennifer R Pyle Alexis Madrack Anne L Donato Dong Cheng James R Paige V Craig Jordan

Aromatase inhibitors (AI) are being evaluated as long-term adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal AI exemestane may exert beneficial effects on bone through its primary metabolite 17-hydroexemestane. We investigated 17-hydroexemestane and observe...

2015
Jiaxin Niu Grant Andres Kim Kramer Madappa N Kundranda Ricardo H Alvarez Eiko Klimant Ankur R Parikh Bradford Tan Edgar D Staren Maurie Markman

BACKGROUND ESR1 mutation has recently emerged as one of the important mechanisms involved in endocrine resistance. The incidence and clinical implication of ESR1 mutation has not been well evaluated in heavily pretreated breast cancer patients. METHODS We conducted a retrospective review of advanced breast cancer patients with tumors who underwent next-generation sequencing genomic profiling ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید